Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

First Posted Date
2018-08-22
Last Posted Date
2023-11-29
Lead Sponsor
Martin Schrappe
Target Recruit Count
5000
Registration Number
NCT03643276
Locations
🇮🇹

AOUC Policlinico Bari, Bari, Italy

🇮🇹

A.O. Papa Giovanni XXIII, Bergamo, Italy

🇮🇹

S.O. Annunziata - A. O. Cosenza, Cosenza, Italy

and more 111 locations

Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia

First Posted Date
2018-08-16
Last Posted Date
2023-06-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
16
Registration Number
NCT03634228
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

First Posted Date
2018-08-09
Last Posted Date
2024-02-13
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
13
Registration Number
NCT03623373
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

First Posted Date
2018-07-19
Last Posted Date
2024-04-05
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
23
Registration Number
NCT03591510
Locations
🇹🇷

Novartis Investigative Site, Istanbul, Turkey

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

First Posted Date
2018-07-18
Last Posted Date
2024-12-17
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
100
Registration Number
NCT03589729
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

First Posted Date
2018-07-17
Last Posted Date
2024-10-31
Lead Sponsor
Takeda
Target Recruit Count
245
Registration Number
NCT03589326
Locations
🇺🇸

Augusta University Georgia Cancer Center, Augusta, Georgia, United States

🇨🇦

Hopital Charles-LeMoyne, Greenfield Park, Quebec, Canada

🇧🇬

University Multiprofile Hospital for Active Treatment Saint Ivan Rilski, Sofia, Sofiya, Bulgaria

and more 89 locations

A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation

First Posted Date
2018-07-13
Last Posted Date
2023-03-16
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
12
Registration Number
NCT03585686
Locations
🇷🇺

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

First Posted Date
2018-07-13
Last Posted Date
2024-11-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
145
Registration Number
NCT03586609
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

First Posted Date
2018-07-11
Last Posted Date
2021-10-06
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
19
Registration Number
NCT03583424
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

First Posted Date
2018-07-09
Last Posted Date
2020-01-29
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT03579927
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy